Hemothorax

Hemothorax is the pathological accumulation of blood within the pleural space. This condition arises from hemorrhage originating from the lungs, heart, great vessels, chest wall, diaphragm, or mediastinal structures. In veterinary medicine, hemothorax is most commonly associated with blunt or penetrating thoracic trauma, but it can also result from coagulopathies, neoplasia, pulmonary thromboembolism, or iatrogenic causes. The accumulation of blood in the pleural cavity compromises pulmonary expansion, leading to ventilation-perfusion mismatch, hypoxemia, and potentially life-threatening respiratory distress. The severity of hemothorax is classified based on the volume of blood loss and the degree of respiratory compromise, ranging from mild, self-limiting effusions to massive hemorrhage with hypovolemic shock. Surgical intervention is indicated for persistent hemorrhage, uncontrolled bleeding, or when thoracostomy tube drainage is ineffective. The surgical approach may involve thoracotomy or thoracoscopy to identify and control the source of bleeding, with techniques including vessel ligation, lung lobectomy, or pericardectomy. Prompt recognition and aggressive management are critical to reduce morbidity and mortality.

The etiology of hemothorax in small animals is diverse, with trauma being the most common cause. Blunt trauma, such as vehicular accidents, falls from heights, or kicks, can cause pulmonary contusions, rib fractures, or laceration of intercostal vessels, leading to hemorrhage into the pleural space. Penetrating trauma, including bite wounds, gunshot injuries, or impalement, can directly damage the lungs, heart, or major vessels. Non-traumatic causes include coagulopathies (e.g., rodenticide intoxication, disseminated intravascular coagulation, hemophilia), neoplasia (e.g., hemangiosarcoma, mesothelioma, pulmonary carcinoma), pulmonary thromboembolism with infarction, and iatrogenic causes such as thoracic surgery, thoracocentesis, or central venous catheter placement. Additionally, spontaneous hemothorax can occur secondary to lung lobe torsion, pulmonary abscessation, or vascular anomalies. The anatomical vulnerability of the thoracic cavity, with its thin-walled vessels and negative pressure, predisposes to rapid accumulation of blood. The cellular mechanisms involve disruption of vascular integrity, activation of the coagulation cascade, and fibrinolysis, which may perpetuate bleeding.

Hemothorax is a relatively common emergency in small animal practice, particularly in dogs and cats presented for trauma. In dogs, the incidence is higher in breeds with a predisposition to thoracic trauma, such as working and hunting breeds (e.g., Labrador Retrievers, German Shepherds) due to increased exposure to vehicular accidents and outdoor activities. Cats are also frequently affected, especially those with outdoor access. There is no significant sex predilection, but young to middle-aged animals are more commonly affected due to higher activity levels and risk of trauma. Coagulopathy-induced hemothorax may be seen in any breed, but certain breeds like Doberman Pinschers and German Shepherds have a higher prevalence of von Willebrand disease, increasing bleeding risk. Neoplastic causes are more common in older animals, with hemangiosarcoma being the most frequent tumor associated with hemothorax, particularly in breeds like Golden Retrievers and German Shepherds. The overall incidence of hemothorax in trauma cases is estimated at 10-20% in dogs and cats, with a higher mortality rate in cases with concurrent pulmonary contusions or cardiovascular compromise.

The pathophysiology of hemothorax involves a cascade of events initiated by hemorrhage into the pleural space. The accumulation of blood exerts pressure on the lungs, leading to atelectasis and reduced functional residual capacity. This results in ventilation-perfusion mismatch, hypoxemia, and respiratory distress. The blood itself acts as a space-occupying lesion, shifting the mediastinum and compressing the contralateral lung, further compromising ventilation. The loss of blood volume leads to hypovolemia, decreased cardiac output, and tissue hypoperfusion, which can progress to hypovolemic shock. The presence of blood in the pleural space triggers an inflammatory response, with activation of the complement system, release of cytokines, and recruitment of neutrophils and macrophages. This can lead to pleuritis and the formation of fibrous adhesions, potentially causing loculation of the effusion and impaired drainage. Additionally, the breakdown of erythrocytes releases hemoglobin and iron, which can be toxic to tissues and promote oxidative stress. Coagulation abnormalities may develop due to consumption of clotting factors and platelets, exacerbating hemorrhage. In chronic cases, the blood may become organized, leading to fibrothorax and restrictive lung disease.

Intrinsic predisposing factors for hemothorax include coagulopathies, such as inherited clotting factor deficiencies (e.g., hemophilia A and B), thrombocytopenia, and platelet dysfunction. Animals with neoplasia, particularly hemangiosarcoma, are at increased risk due to the vascular nature of the tumor and its tendency to rupture. Age is a factor, as older animals are more prone to neoplastic and degenerative conditions. Extrinsic factors include trauma, with high-energy impacts causing more severe thoracic injuries. Environmental factors, such as outdoor access, increase the risk of vehicular accidents and fights with other animals. Iatrogenic factors include thoracic surgery, thoracocentesis, and placement of thoracostomy tubes, which can inadvertently damage vessels. Prior thoracic surgery may leave adhesions that predispose to bleeding. Nutritional deficiencies, such as vitamin K deficiency, can impair coagulation. Excessive physical activity or strenuous exercise may increase intrathoracic pressure and exacerbate bleeding from pre-existing lesions.

Clinical signs of hemothorax vary depending on the volume of blood loss and the rate of accumulation. In mild cases, animals may exhibit tachypnea, mild dyspnea, and lethargy. As the condition progresses, signs of respiratory distress become more pronounced, including increased respiratory effort, orthopnea, cyanosis, and open-mouth breathing in cats. Physical examination reveals muffled heart and lung sounds on auscultation, particularly in the ventral lung fields, due to fluid accumulation. Percussion of the chest may elicit a dull sound. Signs of hypovolemia include pale mucous membranes, prolonged capillary refill time, tachycardia, weak femoral pulses, and cool extremities. In severe cases, animals may present in shock with collapse, bradycardia, and hypotension. Concurrent injuries, such as rib fractures, pulmonary contusions, or diaphragmatic hernia, may be present and complicate the clinical picture. Neurological signs may occur if there is significant hypoxia or head trauma. Chronic hemothorax may lead to weight loss, exercise intolerance, and chronic cough.

Differential diagnoses for hemothorax include other causes of pleural effusion, such as pyothorax, chylothorax, and transudative effusions. Pyothorax is characterized by purulent fluid with a foul odor, and cytology reveals degenerate neutrophils and bacteria. Chylothorax presents with a milky, triglyceride-rich fluid, often due to thoracic duct rupture or neoplasia. Transudative effusions are typically clear and have low protein content, associated with congestive heart failure or hypoalbuminemia. Pulmonary thromboembolism can cause hemorrhagic effusion but is often accompanied by acute onset of dyspnea and risk factors such as hyperadrenocorticism or immune-mediated hemolytic anemia. Lung lobe torsion may present with hemothorax and is more common in deep-chested breeds. Neoplasia, particularly hemangiosarcoma, can cause hemothorax and may be identified on imaging or cytology. Diaphragmatic hernia can mimic hemothorax on radiographs, but the presence of abdominal organs in the thorax is diagnostic. Coagulopathies, such as rodenticide toxicity, should be ruled out with coagulation testing. Iatrogenic causes, such as recent thoracocentesis, should be considered based on history.

The diagnostic algorithm for hemothorax begins with a thorough history and physical examination, focusing on respiratory rate and effort, auscultation, and signs of shock. If the animal is stable, thoracic radiographs are obtained to confirm pleural effusion and assess for concurrent injuries. Radiographic findings include blunting of the costophrenic angles, retraction of lung lobes from the chest wall, and a fluid line. If the animal is unstable, immediate thoracocentesis is performed for both diagnostic and therapeutic purposes. The fluid is evaluated for packed cell volume (PCV), total protein, and cytology; a PCV greater than that of peripheral blood confirms hemothorax. Coagulation testing, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count, is essential to rule out coagulopathy. If trauma is suspected, a focused assessment with sonography for trauma (FAST) can be performed to detect free fluid. Advanced imaging, such as computed tomography (CT), may be indicated in stable animals to identify the source of bleeding, especially if neoplasia is suspected. Thoracoscopy can be both diagnostic and therapeutic, allowing direct visualization of the thoracic cavity and control of hemorrhage. In cases of suspected coagulopathy, specific factor assays may be performed.

Laboratory findings in hemothorax reflect the underlying cause and the degree of blood loss. Complete blood count may reveal anemia, which may be masked initially due to splenic contraction, but becomes evident after fluid resuscitation. Leukocytosis may be present due to stress or inflammation. Platelet count may be decreased in cases of consumptive coagulopathy or immune-mediated disease. Serum biochemistry may show hypoalbuminemia due to protein loss, and elevated liver enzymes if there is concurrent hepatic trauma. Coagulation panel, including PT, aPTT, and fibrinogen, is crucial to identify coagulopathies; prolonged PT and aPTT suggest rodenticide toxicity or liver disease. Thromboelastography (TEG) may provide a more comprehensive assessment of clot formation and lysis. Blood gas analysis may reveal hypoxemia and metabolic acidosis due to hypoperfusion. Inflammatory biomarkers, such as C-reactive protein (CRP) and serum amyloid A (SAA), may be elevated in inflammatory or neoplastic conditions. Thoracocentesis fluid analysis is essential: the fluid is non-clotting, has a PCV greater than 5%, and a total protein greater than 3 g/dL. Cytology may show erythrophagocytosis, and the presence of neoplastic cells may be detected in cases of neoplasia. Bacterial culture and sensitivity should be performed if infection is suspected.

Imaging plays a pivotal role in the diagnosis and management of hemothorax. Thoracic radiography is the initial imaging modality and typically reveals a pleural effusion pattern, with retraction of lung lobes from the thoracic wall, blunting of the costophrenic angles, and a fluid line. In severe cases, a 'white-out' of the hemithorax may be seen. Radiographs may also identify rib fractures, pulmonary contusions, or pneumothorax. Ultrasonography, particularly FAST, is useful in emergency settings to rapidly detect free fluid in the thorax and assess for cardiac tamponade. It can also guide thoracocentesis. Computed tomography (CT) provides detailed cross-sectional images and is superior for identifying the source of hemorrhage, such as a pulmonary mass or vascular injury. CT angiography can delineate vascular anatomy and active bleeding. Magnetic resonance imaging (MRI) is less commonly used but may be helpful in characterizing mediastinal masses. Thoracoscopy is a minimally invasive imaging modality that allows direct visualization of the thoracic cavity, identification of bleeding sites, and therapeutic intervention. Fluoroscopy may be used during interventional procedures, such as embolization of bleeding vessels.

Cytological evaluation of pleural fluid in hemothorax typically shows a hemorrhagic effusion with a high red blood cell count, and the fluid PCV is usually greater than that of peripheral blood. Macrophages containing phagocytized erythrocytes (erythrophagocytosis) are commonly seen, especially in chronic cases. The presence of neutrophils may indicate concurrent inflammation or infection. If neoplasia is suspected, cytology may reveal malignant cells, such as in hemangiosarcoma, where spindle cells with high nuclear-to-cytoplasmic ratio and mitotic figures may be observed. However, cytology has low sensitivity for detecting neoplasia in hemorrhagic effusions. Histopathology is more definitive and is obtained from tissue biopsies during thoracoscopy or thoracotomy. In cases of hemangiosarcoma, histopathology shows poorly differentiated endothelial cells forming vascular channels, with areas of necrosis and hemorrhage. Immunohistochemistry for factor VIII-related antigen or CD31 can confirm endothelial origin. In cases of mesothelioma, histopathology may show papillary or tubulopapillary growth patterns, and immunohistochemistry for calretinin or cytokeratin is helpful. Surgical biopsy of the pleura or lung may be necessary to establish a definitive diagnosis when the underlying cause is unclear.

Treatment of hemothorax depends on the underlying cause and the severity of hemorrhage. Initial stabilization includes oxygen supplementation, intravenous fluid resuscitation with crystalloids or colloids, and blood transfusion if significant blood loss has occurred. Thoracocentesis or thoracostomy tube placement is performed to evacuate blood and relieve respiratory distress. In cases of mild, self-limiting hemorrhage, conservative management with thoracocentesis and monitoring may be sufficient. However, if hemorrhage is persistent or severe, surgical intervention is indicated. Surgical options include thoracotomy or thoracoscopy. Thoracotomy may be performed via a lateral intercostal approach or median sternotomy, depending on the suspected source of bleeding. The surgical technique involves exploring the thoracic cavity, identifying the bleeding site, and controlling hemorrhage via ligation of vessels, electrocautery, or surgical clips. Lung lobectomy may be necessary if the hemorrhage originates from a lung lobe. In cases of cardiac or great vessel injury, primary repair may be attempted. Pericardectomy may be performed if the source is a bleeding pericardial mass. Postoperative management includes continued thoracic drainage, pain management, and monitoring for complications such as re-bleeding, infection, or respiratory distress. In cases of coagulopathy, specific treatment such as vitamin K administration or plasma transfusion is required.

The prognosis for hemothorax depends on the underlying cause, the severity of hemorrhage, and the timeliness of intervention. In cases of mild trauma-induced hemothorax, the prognosis is generally good with conservative management, with most animals recovering within a few days. However, the prognosis is guarded to poor in cases of severe hemorrhage, especially if associated with major vascular injury or cardiac trauma. The presence of concurrent injuries, such as pulmonary contusions or diaphragmatic hernia, worsens the prognosis. Neoplastic causes, particularly hemangiosarcoma, carry a poor prognosis due to the aggressive nature of the tumor and high likelihood of metastasis. The median survival time for dogs with hemangiosarcoma and hemothorax is typically less than 3 months, even with surgery and chemotherapy. Coagulopathy-induced hemothorax has a variable prognosis depending on the underlying coagulopathy and response to treatment. Complications such as re-bleeding, infection, or fibrothorax can negatively impact the outcome. Overall, the mortality rate for hemothorax in small animals is reported to be 10-30%, with higher rates in cases requiring surgical intervention.

Follow-up care for hemothorax is essential to monitor for recurrence and ensure complete resolution. After initial treatment, animals should be re-evaluated within 24-48 hours with thoracic radiographs to assess for residual fluid or re-accumulation. If a thoracostomy tube is in place, it is typically removed when drainage is less than 2-3 ml/kg/day and the lungs are fully expanded. Suture removal from surgical incisions is usually performed at 10-14 days postoperatively. Serial thoracic radiographs are recommended at 2, 4, and 8 weeks after discharge to confirm resolution of the effusion and to detect any late complications such as fibrothorax or recurrence of neoplasia. Activity should be restricted for 4-6 weeks after surgery to allow healing. Physical rehabilitation, including controlled leash walks and respiratory exercises, may be beneficial. In cases of coagulopathy, regular monitoring of coagulation parameters is necessary. For neoplastic causes, oncologic follow-up with chemotherapy and repeat imaging is indicated. Long-term monitoring for chronic respiratory signs or exercise intolerance is recommended.

Clinical pearls: 1) Always assess for coagulopathy before surgical intervention, as surgery in a coagulopathic patient can be catastrophic. 2) In trauma cases, perform a FAST scan to rapidly detect hemothorax and guide initial management. 3) When performing thoracocentesis, use a butterfly catheter or over-the-needle catheter to minimize the risk of lung laceration. 4) If the hemothorax is due to a lung lobe torsion, the affected lobe is often dark and consolidated; a lung lobectomy is curative. 5) In cases of persistent hemorrhage, consider autotransfusion of the collected blood if sterile and if the animal is stable. Pitfalls: 1) Do not delay thoracostomy tube placement in a dyspneic animal; it can be life-saving. 2) Avoid overzealous fluid resuscitation, which can worsen bleeding by increasing blood pressure. 3) Do not assume that a hemorrhagic effusion is traumatic; always rule out neoplasia and coagulopathy. 4) In surgical cases, ensure adequate exposure and lighting to identify the bleeding source; a median sternotomy provides excellent access to both hemithoraces. 5) Postoperative monitoring for re-bleeding is crucial; a sudden increase in drainage or deterioration in respiratory status warrants immediate re-evaluation.

Perioperative pharmacological protocols for hemothorax are based on Plumb's Veterinary Drug Handbook. Prophylactic antimicrobials: Cefazolin (22 mg/kg IV) administered 30 minutes before surgical incision and repeated every 90 minutes during surgery. Postoperative antibiotics are not routinely indicated unless there is contamination or infection. Analgesics: Opioids such as hydromorphone (0.05-0.1 mg/kg IV or IM q4-6h) or fentanyl (2-5 mcg/kg IV bolus, then 2-6 mcg/kg/h CRI) are used for pain management. Non-steroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) may be used after the animal is hemodynamically stable, but caution is advised in cases of renal compromise or coagulopathy. Local anesthetic blocks, such as intercostal nerve blocks with bupivacaine (1-2 mg/kg, maximum 2 mg/kg) or lidocaine (1-2 mg/kg), can provide additional analgesia. For coagulopathy, vitamin K1 (2.5-5 mg/kg PO or SC q12h for 2-4 weeks) is used for rodenticide toxicity. Fresh frozen plasma (10-20 ml/kg IV) may be administered to replace clotting factors. In cases of severe anemia, packed red blood cells (10-20 ml/kg IV) are transfused. Bronchodilators such as aminophylline (10 mg/kg IV or PO q8h) may be used if bronchospasm is present. Oxygen supplementation is provided as needed.

Evidence-based literature on hemothorax in small animals is limited, but several key studies provide guidance. A retrospective study by Spackman et al. (1984) reported that hemothorax in dogs was most commonly caused by trauma, and conservative management with thoracocentesis was successful in many cases. Another study by Boudrieau et al. (1985) evaluated the use of autotransfusion in dogs with hemothorax and found it to be a safe and effective method to restore blood volume. A more recent study by Sigrist et al. (2011) assessed the utility of FAST in detecting hemothorax in dogs with blunt trauma, demonstrating high sensitivity and specificity. In terms of surgical management, a study by Monnet (2003) reviewed thoracoscopic techniques for treating thoracic disease, including hemothorax, and reported favorable outcomes with minimally invasive approaches. Regarding coagulopathy-induced hemothorax, a study by Murphy et al. (2013) highlighted the importance of early diagnosis and treatment of rodenticide toxicity. For neoplastic causes, a study by Hammer et al. (1993) reported that dogs with hemangiosarcoma and hemothorax had a poor prognosis, with a median survival of less than 3 months despite surgery and chemotherapy. Consensus guidelines from the American College of Veterinary Surgeons (ACVS) and the European College of Veterinary Surgeons (ECVS) recommend a systematic approach to the diagnosis and management of pleural effusion, including hemothorax, emphasizing the importance of rapid stabilization and surgical intervention when indicated.